drugset
drugset / Trial / NCT06990464

A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients

NCT06990464 ↗

Phase 1 Recruiting 156 enrolled Shanghai Institute Of Biological Products
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A19 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).

Timeline

Start
2025-06-11
Primary completion
2028-12-15
Completion
2028-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject SIBP-A19 Unknown 1 mg/kg Intravenous
Subject SIBP-A19 Unknown 2 mg/kg Intravenous
Subject SIBP-A19 Unknown 3.2 mg/kg Intravenous
Subject SIBP-A19 Unknown 4 mg/kg Intravenous
Subject SIBP-A19 Unknown 4.8 mg/kg Intravenous
Subject SIBP-A19 Unknown 5.6 mg/kg Intravenous
Subject SIBP-A19 Unknown 6.4 mg/kg Intravenous
Subject SIBP-A19 Unknown 8 mg/kg Intravenous

Indications

cancer